期刊
NATURE
卷 584, 期 7821, 页码 437-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41586-020-2456-9
关键词
-
资金
- NIH [P01-AI138398-S1, 2U19AI111825]
- Caltech Merkin Institute for Translational Research
- George Mason University
- European ATAC consortium [EC 101003650]
- G. Harold and Leila Y. Mathers Charitable Foundation
- Robert S. Wennett Post-Doctoral Fellowship
- National Center for Advancing Translational Sciences (National Institutes of Health Clinical and Translational Science Award programme) [UL1 TR001866]
- Shapiro-Silverberg Fund for the Advancement of Translational Research
- [P50 AI150464]
- [R01-AI091707-10S1]
- [R37-AI64003]
- [R01AI78788]
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2(1-5). Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC(50)values) as low as 2 ng ml(-1). In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective. Although rare, antibodies against the receptor-binding domain of SARS-CoV-2 that showed potent antiviral activity were obtained from all tested convalescent individuals, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据